In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Corp.

www.bostonscientific.com

Latest From Boston Scientific Corp.

Manufacturers Support CMS’ New TAVR National Coverage Decision

CMS has completed its new national Medicare Coverage with Evidence Development policy for transcatheter aortic valve replacement. The final decision memo largely maintains the recommendations from the draft version released in March, including more flexible criteria for centers establishing TAVR programs, while emphasizing the importance of the interdisciplinary heart team for decision-making about valve replacement.

Medicare Reimbursement

Biotronik Addresses US CRM Market With Its Rivacor And Acticor Lines

The company recently launched six new implantable high-voltage cardiac rhythm management devices with the thin elliptical BIOshape to minimize the risk of skin erosion around the device pocket. Rivacor and Acticor also feature Biotronik's DX leadless atrial diagnostic technology, and MRI AutoDetect which automatically switches the device to a MR-safe mode when it enters a magnetic resonance imaging environment.

Approvals Cardiology

FDI In India’s Medical Devices Sector Plunges, Experts Blame Price Controls

FDI in India's medtech sector has plunged to levels last seen before investment in the sector was liberalized and the Indian association representing global medical technology firms says government-imposed price controls are to blame.

India Pricing Strategies

UNTOUCHED Trial Shows Low Complication Rate With Boston Scientific’s Emblem S-ICD

Procedural outcome data of the UNTOUCHED trial of the Emblem subcutaneous implantable cardioverter defibrillator show low perioperative complication rates and high conversion efficacy of induced ventricular fibrillation in a high-risk patient population.

Clinical Trials Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register